Skip Navigation


JAC Advance Access originally published online on March 7, 2008
Journal of Antimicrobial Chemotherapy 2008 61(5):1083-1086; doi:10.1093/jac/dkn076
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/5/1083    most recent
dkn076v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de la Escalera, C. M.
Right arrow Articles by Martín-Mazuelos, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de la Escalera, C. M.
Right arrow Articles by Martín-Mazuelos, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Activity of BAL 4815 against filamentous fungi

C. Martín de la Escalera1,*, A. I. Aller1, E. López-Oviedo1, A. Romero1, A. I. Martos1, E. Cantón2, J. Pemán2, P. García Martos3 and E. Martín-Mazuelos1

1 Servicio de Microbiología y Parasitología, Hospital Universitario de Valme, Carretera de Cádiz s/n, Sevilla, Spain 2 Hospital La Fe, Avda. Campanar 21, Valencia 46009, Spain 3 Hospital Puerta del Mar, Avda. Ana de Viya 21, Cádiz, 11009, Spain

* Corresponding author. Tel: +34-955015480; Fax: +34-955015481; E-mail: cemarmar{at}gmail.com

Received 14 May 2007; returned 3 July 2007; revised 28 January 2008; accepted 1 February 2008


   Abstract
Top
 Abstract
Introduction
 Materials and methods
 Results
 Discussion
 Funding
 Transparency declarations
 References
 
Objectives: BAL 4815 is a new antifungal drug and it is the active component of the antifungal triazole BAL 8557 (the water-soluble precursor). We studied the in vitro fungistatic and fungicidal activities of BAL 4815 against 103 clinical isolates of filamentous fungi, including 51 isolates of Aspergillus spp. and 52 isolates of non-Aspergillus filamentous fungi.

Methods: We evaluated the in vitro activity of BAL 4815 against 51 isolates of Aspergillus spp., 20 isolates of dematiaceous fungi, 18 isolates of hyaline Hyphomycetes and 14 isolates of Zygomycetes. MICs were determined following the CLSI M38-A broth microdilution method, using RPMI 1640 medium buffered to pH 7.0 with MOPS. Microdilution plates were incubated at 35°C and read at 24 and 48 h (Mucorales were read at 24 h). Minimal fungicidal concentrations were also determined.

Results: For all isolates, geometric mean MICs, MIC50s, MIC90s and MIC ranges (mg/L) were: Aspergillus spp., 1.67, 2, 4 and 0.5–4; dematiaceous fungi, 1.62, 1, >8 and 0.03 to >8; hyaline Hyphomycetes, 2.41, 2, >8 and 0.03 to >8; and Zygomycetes, 6.81, 8, >8 and 0.03 to >8. Differences in susceptibility between genera were noted. Scedosporium prolificans, Fusarium spp., Mucor spp. and Rhizopus spp. (MIC90 > 8 mg/L) were less susceptible than Aspergillus spp. (MIC90 = 4 mg/L).

Conclusions: BAL 4815 has excellent in vitro activity against Aspergillus spp. and variable activity against other filamentous fungi.

Keywords: Aspergillus , triazoles , antifungals


   Introduction
Top
 Abstract
 Introduction
Materials and methods
 Results
 Discussion
 Funding
 Transparency declarations
 References
 
Despite advances in antifungal therapy, invasive infections due to Aspergillus spp. and other filamentous fungi (moulds) have emerged as prominent causes of morbidity and mortality worldwide in immunocompromised hosts, remaining unacceptably high.1 Amphotericin B has been the key systemic antifungal therapy for many years; concerns regarding its toxicity have been partially addressed by the introduction of lipid formulations, but significant toxicity still remains, often causing therapy withdrawal.2 Since the discovery of the antifungal activity of the first azoles, huge advances have been made in this group to reduce toxicity, enhance bioavailability, improve the antifungal spectrum and counteract resistance. Voriconazole exhibits excellent in vitro and in vivo activity against Aspergillus species,3 and the new triazoles, ravuconazole and posaconazole have excellent in vitro activity against Aspergillus spp. and other filamentous fungi.4 BAL 4815 is a new, water-insoluble, investigational triazole with in vitro and in vivo activity against yeasts and moulds, and is the active antifungal component of BAL 8557 (the water-soluble prodrug suitable for oral and intravenous delivery);5 very low levels of cleavage product are detectable in the serum after oral or intravenous administration and it is not necessary to add potentially toxic cyclodextrin to increase or achieve solubility of this new azole as happens in itraconazole and voriconazole intravenous solutions. At the end of 1 h infusion of 50, 100 and 200 mg, Cmax values of BAL 4815 reached 0.446, 1.03 and 2.47 mg/L, respectively. The corresponding AUC{infty} values were 11.3, 26.6 and 73.2 µg·h/mL.6

We studied the in vitro activity of BAL 4815 against 103 isolates of filamentous fungi. Susceptibilities were determined using the broth microdilution method in accordance with the CLSI (formerly the NCCLS) reference method for microdilution antifungal susceptibility testing of filamentous fungi (M38-A).7


   Materials and methods
Top
 Abstract
 Introduction
 Materials and methods
Results
 Discussion
 Funding
 Transparency declarations
 References
 
Susceptibility tests were performed on 103 filamentous fungi isolates comprising 51 Aspergillus spp. (19 Aspergillus terreus, 14 Aspergillus fumigatus, 12 Aspergillus flavus, 3 Aspergillus glaucus, 2 Aspergillus niger and 1 Aspergillus nidulans), 20 dematiaceous fungi (7 Scedosporium apiospermum, 5 Scedosporium prolificans, 2 Rhinocladiella spp., 1 Hortaea werneckii, 1 Phialophora sp., 1 Stachybotrys sp., 1 Curvularia sp., 1 Bipolaris sp. and 1 Phoma sp.), 18 hyaline Hyphomycetes (10 Fusarium spp., 2 Scopulariopsis spp., 2 Acremonium spp., 1 Trichoderma sp., 1 Verticillium sp., 1 Paecilomyces sp. and 1 Arthrographis sp.) and 14 Zygomycetes (6 Mucor spp., 5 Rhizopus spp., 1 Cunninghamella bertholletiae, 1 Absidia corymbifera and 1 Syncephalastrum sp.). These isolates were recovered from clinical specimens received in Valme University Hospital in Seville (Spain), Puerta del Mar University Hospital in Cadiz (Spain) and La Fe University Hospital in Valencia (Spain). Identification of each isolate was performed using conventional mycological techniques. Mould isolates were maintained in sterile water and were subcultured on antimicrobial agent-free potato dextrose agar (Difco Laboratories, Detroit, MI, USA) to ensure viability and purity.

Candida krusei ATCC 6258, Candida parapsilosis ATCC 22019, A. flavus ATCC 204304 and A. fumigatus 204305 were included in each susceptibility test for quality control (QC) and assessment of reproducibility testing.

BAL 4815 (Basilea Pharmaceutica, Basel, Switzerland) was provided as a pure powder by the manufacturer and it was dissolved in 100% dimethyl sulphoxide. The broth microdilution test was done in accordance with the CLSI guidelines for filamentous fungi (CLSI document M38-A) using RPMI 1640 medium (Sigma Chemical Co., St Louis, MO, USA) buffered to pH 7.0 with MOPS (Sigma). Final drug range was 0.015–8 mg/L. Stock inoculum suspensions were prepared from 7-day-old cultures grown on potato dextrose agar following the CLSI guidelines (document M38-A). Stock suspensions were adjusted spectrophotometrically to optical densities that ranged from 0.09 to 0.11 (80% to 82% transmittance) and contained conidia or sporangiospores. The diluted (2x) inoculum sizes ranged from 0.9 x 104 to 4.7 x 104 cfu/mL, as demonstrated by quantitative colony counts on Sabouraud dextrose agar. Drug-free and cell-free controls were included. The microdilution plates were incubated and read after 24 and 48 h of incubation at 35°C except for the Zygomycetes, which were read at 24 h. The MIC endpoints were read visually with the aid of a reading mirror at the lowest drug concentration that prevented 100% growth at 24 h (Zygomycetes) and 48 h of incubation at 35°C.

The minimal fungicidal concentration (MFC) of each agent was determined according to Espinel-Ingroff et al.8 Briefly, 20 µL aliquots of broth were subcultured from each well that showed complete inhibition of growth (100%, or an optically clear well), from the growth control well (drug-free medium) and from the last positive well (with growth similar to that in the growth control well) onto Sabouraud dextrose agar (Oxoid, Basingstoke, UK) plates. The plates were incubated at 35°C until growth was seen in the growth control subculture (usually 48 h later). The MFC was defined as the lowest drug concentration that resulted in either no growth or growth of fewer than three colonies, which corresponds to a killing activity of 99.0% to 99.5%. The drug showed fungicidal activity when MFC was within two dilutions of the MIC.

For analysis of the results, geometric means (GMs), ranges of MICs, MIC50 and MIC90 values were calculated. MIC50 and MIC90 values were calculated as the lowest drug concentrations that prevented 100% growth of 50% and 90% of all the isolates, respectively, and MFC50 and MFC90 values were calculated as the lowest drug concentrations that prevented 99.0% to 99.5% growth of 50% and 90% of the isolates, respectively.


   Results
Top
 Abstract
 Introduction
 Materials and methods
 Results
Discussion
 Funding
 Transparency declarations
 References
 
Table 1 shows the results of the in vitro susceptibility values against 103 filamentous fungi obtained after 48 h of incubation except for Zygomycetes, which could not be interpreted at 48 h, as they had no MIC by over growth. The GM MICs, MIC ranges and MIC50/MIC90 values (mg/L) were, respectively: Aspergillus spp., 1.67, 0.5–4 and 2/4; dematiaceous fungi, 1.62, 0.03 to >8 and 1/>8; hyaline Hyphomycetes, 2.41, 0.03 to >8 and 2/>8; and Zygomycetes, 6.81, 0.5 to >8 and 8/>8.


View this table:
[in this window]
[in a new window]

  		Table 1. In vitro susceptibilities of 103 isolates of filamentous fungi to BAL 4815

 
For Aspergillus spp., BAL 4815 showed higher activity against A. terreus (MIC50/MIC90 = 1/2 mg/L) than the other species of Aspergillus (MIC50/MIC90 = 2/4 mg/L).

For non-Aspergillus filamentous fungi, the activity of BAL 4815 was variable. For dematiaceous fungi, BAL 4815 showed higher activity against non-Scedosporium spp. isolates (MIC50 and MIC90 of 0.5 and 4 mg/L, respectively) than for Scedosporium spp. (MIC50 = 1 and MIC90 = ≥8 mg/L). For hyaline Hyphomycetes, BAL 4815 was more active against isolates of Scopulariosis spp., Trichoderma spp., Verticillium spp., Paecilomyces spp. and Arthrographis spp. (MIC50 = 0.5 and MIC90 = 4 mg/L) than for Fusarium spp. (MIC50 = 4 and MIC90 = >8 mg/L) and Acremonium spp. (MIC = >8 mg/L). For Zygomycetes, MIC50/MIC90 values were high for Mucor spp. and Rhizopus spp. (8 and >8 mg/L, respectively), and in other Zygomycetes, the activity of BAL 4815 was variable: A. corymbifera, MIC = 1; Syncephalastrum, MIC = 4; and C. bertholletiae, MIC = >8 mg/L.

For all isolates, GM MFC values and ranges (mg/L) were: Aspergillus spp., 3.77 and 1–8; dematiaceous fungi, 0.99 and 0.03 to >8; hyaline Hyphomycetes, 1.49 and 0.06 to >8; and Zygomycetes, 4 and 1 to >8. BAL 4815 was fungicidal in 98.5%, and the MFC50 and MFC90 were, respectively: Aspergillus spp., 4.0 and 8.0; dematiaceous fungi, 1.0 and 8.0; hyaline Hyphomycetes, 2.0 and 8.0; and Zygomycetes, 4.0 and 8.0.

MFCs were determined only for wells that showed complete inhibition of growth. We calculated GM MFCs and MFC50/90s only when 10 or more strains were available.

MIC50/90s and MFCs (mg/L) of QC strains were: C. krusei ATCC 6258, 0.5/1 and 4; C. parapsilosis ATCC 22019, 0.5/1 and 2; A. flavus ATCC 204304, 2/4 and 8; and A. fumigatus 204305, 1/2 and 2.

The MFC value was the same as or only one dilution higher than the MIC for 92% of Aspergillus spp., 100% of dematiaceous fungi, 92% of hyaline Hyphomycetes and 100% of Zygomycetes (the isolates with an MIC of 8 mg/L of BAL 4815 were not used in this analysis of the data). The reproducibility study on 19% of the isolates showed that 75% of isolates retested were within one dilution of the original MIC value of BAL 4815.


   Discussion
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
Funding
 Transparency declarations
 References
 
There are few studies that have evaluated the activity of this new antifungal azole against filamentous fungi and they include a low number of isolates. Our results are difficult to compare with those of other authors who also tested filamentous fungi because they used other azoles.

Recently, Warn et al.9 reported that BAL 4815 showed primary fungicidal activity against all four Aspergillus species tested (A. fumigatus, A. terreus, A. flavus and A. niger), finding that A. terreus was more susceptible to BAL 4815 than A. flavus and A. niger, which is in agreement with the results obtained in our study.

In relation to non-Aspergillus filamentous fungi, MIC50 values for dematiaceous fungi, hyaline Hyphomycetes and Zygomycetes in our study were lower than those obtained by Gonzalez and Heep.10 Non-Scedosporium dematiaceous fungi and other hyaline Hyphomycetes (Paecilomyces sp.) had an MIC50 of 0.5 mg/L, Fusarium spp. had an MIC50 of 4 mg/L and A. corymbifera had an MIC50 of 1 mg/L. Gonzalez and Heep obtained an MIC50 of 2 mg/L for non-Scedosporium dematiaceous fungi, an MIC50 of 1 mg/L for other hyaline Hyphomycetes, an MIC50 of 8 mg/L for Fusarium spp. and an MIC50 of 4 g/L for A. corymbifera. Mucor spp. and Rhizopus spp. had the same values or slightly higher in our study, and the MIC ranges, MIC50s, MIC90s and GM MICs at 48 h were slightly higher than those presented by Warn et al.11

In the present study, the non-Aspergillus filamentous fungi most susceptible to BAL 4815 were the non-Scedosporium dematiaceous fungi (Rhinocladiella spp., H. werneckii, Phialophora sp., Stachybotrys sp., Curvularia sp., Bipolaris sp. and Phoma sp.). BAL 4815 did not show fungicidal activity against S. prolificans (MIC90 > 8 mg/L); there are no published data with BAL 4815 and this species, although other authors also found MICs/MFCs > 8 mg/L of posaconazole, itraconazole and voriconazole for S. prolificans.12,13

The new triazoles (posaconazole, ravuconazole and posaconazole) have demonstrated some activity against miscellaneous moulds, but none of these agents had good in vitro activity against Fusarium spp. (MIC90 > 8 mg/L).12–16 Our findings for BAL 4815 against Fusarium spp. are in agreement with previously published in vitro data for other azoles.12,13

We report in vitro results in agreement with other authors12–16 for 14 Zygomycetes, although the Zygomycetes are a heterogeneous group with regard to antifungal susceptibility testing.17 Warn et al.9 demonstrated that BAL 4815 showed primary fungicidal activity (MFC within two dilutions of the MIC) against all Aspergillus species tested. In our study against Aspergillus spp. and non-Aspergillus spp., 98.7% of isolates had the MFC within one dilution of the MIC.

Indeed, 71% of isolates of Aspergillus spp. were killed at ≤2.0 mg/L BAL 4815, in agreement with Warn et al.,5 and 25% of isolates of non-Aspergillus filamentous fungi were killed at 4 mg/L.

In summary, we found that BAL 4815 has excellent in vitro activity against Aspergillus spp. and variable activity against other filamentous fungi. Therefore, further in vitro and in vivo studies are necessary in order to verify the antifungal activity of this azole.


   Funding
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
Transparency declarations
 References
 
This work was supported in part by the Unit of Investigation of Microbiology of Valme University Hospital. No other funding was provided for the work.


   Transparency declarations
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
 Transparency declarations
References
 
None to declare.


   Acknowledgements
 
We thank Basilea Pharmaceutica for providing BAL 4815 as a pure powder at no cost.


   References
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
 Transparency declarations
 References
 
1 Groll AH, Kurz M, Scheneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre: epidemiology, management and long-term survival. Mycoses (1999) 42:431–42.[CrossRef][Web of Science][Medline]

2 Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2002) 35:359–66.[CrossRef][Web of Science][Medline]

3 Manavathu EK, Cutright JL, Loebenberg D, et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH56592). J Antimicrob Chemother (2000) 46:229–34.[Abstract/Free Full Text]

4 Diekema DJ, Messer SA, Hollins RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol (2003) 41:3623–6.[Abstract/Free Full Text]

5 Warn P, Sharp A, Denning D, et al. In vitro activity of a new triazole BAL8557, the water-soluble prodrug of BAL4815, in a temporarily neutropenic murine model of disseminated Aspergillus flavus. In: Med Mycol (2005) 43. Abstracts of the First Advances Against Aspergillosis Conference, 2004: San Francisco, CA, USA. (Suppl 1):105. Abstract 86.[Medline]

6 Schmitt-Hoffman A, Ross B, Heep M, et al. Pharmacokinetics of BAL4815, a new azole antifungal, after administration of single ascending intravenous doses of its pro-drug BAL8557. In: Abstracts of the Fourteenth European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases. Poster P1033.

7 National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A (2002) Wayne, PA, USA: NCCLS.

8 Espinel-Ingroff A, Fothergill A, Peter J, et al. Testing conditions for determination of minimal fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS Collaborative Study. J Clin Microbiol (2002) 40:3204–8.[Abstract/Free Full Text]

9 Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother (2006) 57:135–8.[Abstract/Free Full Text]

10 Gonzalez G, Heep M. In vitro activity of BAL4815, a new water-soluble broad spectrum triazole, against opportunistic filamentous and dimorphic fungi. Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology, 2006: Paris, France. Abstract P-0081.

11 Warn P, Sharp A, Denning D. In vitro activity of BAL 4815 against zygomycetes. Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology, 2006: Paris, France. Abstract P-0158.

12 Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol (2001) 39:954–8.[Abstract/Free Full Text]

13 López-Oviedo E, Aller AI, Martín C, et al. Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method. Antimicrob Agents Chemother (2006) 50:1108–11.[Abstract/Free Full Text]

14 Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinicandins MK-0091 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol (1998) 36:2950–6.[Abstract/Free Full Text]

15 Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother (2002) 46:1032–7.[Abstract/Free Full Text]

16 Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol (2003) 41:3623–6.[Abstract/Free Full Text]

17 Dannaoui E, Meletiadis J, Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 51:45–52.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Schmitt-Hoffmann, B. Roos, J. Spickermann, M. Heep, E. Peterfai, D. J. Edwards, and K. Stoeckel
Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557
Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4885 - 4890.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Perkhofer, V. Lechner, and C. Lass-Florl
In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1645 - 1647.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/5/1083    most recent
dkn076v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de la Escalera, C. M.
Right arrow Articles by Martín-Mazuelos, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de la Escalera, C. M.
Right arrow Articles by Martín-Mazuelos, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?